Skip to main content
. 2020 Nov 3;5(6):e000944. doi: 10.1136/esmoopen-2020-000944

Figure 2.

Figure 2

Kaplan-Meier estimates of (A) progression-free survival and (B) overall survival in the intention-to-treat population. FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; FOLFOXIRI, 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.